newsfilter
← Latest News
GlobeNewswire·

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

AEMD
  • Aethlon Medical, Inc. (NASDAQ: AEMD) CEO & CFO Jim Frakes will present live at the Life Sciences Investor Forum on March 12, 2026, from 1:00–1:30 pm ET.
  • The online forum allows real-time Q&A with management, includes replay availability, & offers 1x1 investor meetings on the event date.
  • Cohort 2 of the Australian oncology trial is actively progressing.
  • Preclinical extracellular vesicle (EV) research continues, with Long COVID data published on bioRxiv & submitted for peer review.
  • The company is evaluating Hemopurifier compatibility with a simplified blood treatment system for broader clinical application.
  • Year-to-date operating expenses are lower than the prior year due to disciplined cost controls.
  • The investigational Hemopurifier device removes enveloped viruses & tumor-derived EVs using plasma separation, size exclusion, & affinity binding.
  • The device holds FDA Breakthrough Device Designation for advanced/metastatic cancer & life-threatening viruses not addressed by approved therapies.
  • Aethlon Medical is a clinical-stage company headquartered in San Diego focused on removing pathogenic targets from biologic fluids.
  • Forward-looking statements warn of risks including potential cash insufficiency for the next 12 months, capital raising challenges, trial completion uncertainty, & regulatory hurdles.